These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27170382)

  • 1. Chronic Hepatitis D; at a Standstill?
    Rizzetto M
    Dig Dis; 2016; 34(4):303-7. PubMed ID: 27170382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drugs in development for Hepatitis D.
    Rizzetto M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hepatitis D.
    Rizzetto M
    Semin Liver Dis; 2018 Feb; 38(1):66-72. PubMed ID: 29471567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis D: an unmet medical need.
    Caviglia GP; Rizzetto M
    Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adventure of delta.
    Rizzetto M
    Liver Int; 2016 Jan; 36 Suppl 1():135-40. PubMed ID: 26725911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.
    Niro GA; Smedile A; Fontana R; Olivero A; Ciancio A; Valvano MR; Pittaluga F; Coppola N; Wedemeyer H; Zachou K; Marrone A; Fasano M; Lotti G; Andreone P; Iacobellis A; Andriulli A; Rizzetto M
    Aliment Pharmacol Ther; 2016 Sep; 44(6):620-8. PubMed ID: 27443972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis D at a standstill: where do we go from here?
    Ciancio A; Rizzetto M
    Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):68-71. PubMed ID: 24019153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis delta and HIV infection.
    Soriano V; Sherman KE; Barreiro P
    AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future treatments for hepatitis delta virus infection.
    Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
    Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
    Koh C; Canini L; Dahari H; Zhao X; Uprichard SL; Haynes-Williams V; Winters MA; Subramanya G; Cooper SL; Pinto P; Wolff EF; Bishop R; Ai Thanda Han M; Cotler SJ; Kleiner DE; Keskin O; Idilman R; Yurdaydin C; Glenn JS; Heller T
    Lancet Infect Dis; 2015 Oct; 15(10):1167-1174. PubMed ID: 26189433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
    Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
    Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
    Lempp FA; Ni Y; Urban S
    Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
    Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
    Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
    Zachou K; Yurdaydin C; Drebber U; Dalekos GN; Erhardt A; Cakaloglu Y; Degertekin H; Gurel S; Zeuzem S; Bozkaya H; Schlaphoff V; Dienes HP; Bock TC; Manns MP; Wedemeyer H;
    Liver Int; 2010 Mar; 30(3):430-7. PubMed ID: 19840253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.
    Madejón A; Romero M; Hernández Á; García-Sánchez A; Sánchez-Carrillo M; Olveira A; García-Samaniego J
    World J Gastroenterol; 2016 Mar; 22(11):3165-74. PubMed ID: 27003993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamivudine for chronic delta hepatitis.
    Lau DT; Doo E; Park Y; Kleiner DE; Schmid P; Kuhns MC; Hoofnagle JH
    Hepatology; 1999 Aug; 30(2):546-9. PubMed ID: 10421666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging concepts for the treatment of hepatitis delta.
    Elazar M; Glenn JS
    Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.